With CURE® TV, you have access to a variety of informative and uplifting videos. You’ll find interviews with cancer experts, advocates, patients, caregivers, as well as highlights from our celebratory events showcasing interviews with award winners and celebrity speakers.

When Art Meets Cancer Science

December 9th 2020, 4:00pm


Street artist James Cochran gives CURE® an inside look at his newest project: a piece of art he created by applying 50,000 small dots of paint to a canvas using a lab pipette. It will be displayed in the Institute of Cancer Research’s Centre for Cancer Drug Discovery as a symbol of the creativity and commitment of the scientists who work every day to eradicate cancer.

Long-Term Data of Imbruvica-Rituxan Combo in Waldenstrom’s Macroglobulinemia Demonstrates ‘Major Step Forward’

December 8th 2020, 2:15pm


In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan.

Imbruvica-Based Treatment Elicited Long-Term Survival Benefits in Subset of Patients With CLL Who Historically Have Poor Outcomes

December 7th 2020, 8:00pm


Imbruvica treatment in patients with chronic lymphocytic leukemia whose disease expressed a certain mutation elicited sustained efficacy over a median follow-up of four years, according to data from a long-term analysis.

Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited

December 7th 2020, 2:00pm


In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.

How Higher Doses of Imetelstat May Benefit Patients with Relapsed/Refractory Myelofibrosis

December 6th 2020, 6:23pm


In an interview with CURE®, lead study investigator Dr. John Mascarenhas discusses what the results of the phase 2 IMbark study could mean for the future of patients with myelofibrosis.

Adaptive Clinical Trial Design Aims to Accelerate Research and Approvals in Pancreatic Cancer

December 2nd 2020, 10:00pm


The research process for pancreatic cancer is long and difficult, but a new method of clinical trials is looking to adapt to a growing field and find ways to speed up research without losing efficiency.

How Theranostics Differs From the Current Prostate Cancer Treatment Options

December 1st 2020, 10:00pm


While the current field of prostate cancer research is experiencing an era of “warp speed developments,” perhaps the most exciting option on the horizon is theranostics, according to Dr. Phillip J. Koo.

How the Cancer Care Team is Like a Symphony Orchestra

November 30th 2020, 4:00pm


Often, patients with cancer will come into contact with only a handful of members of their care team: a primary care physician or oncologist, perhaps a nurse or two. But as Dr. Phillip J. Koo explained, it helps to view the cancer care team – including those who a patient may never see – with a wider lens.

How Theranostics Could Impact the Future of Prostate Cancer Treatment

November 27th 2020, 2:00pm


The field of theranostics is growing, and its impact could change the future of prostate cancer treatment. CURE® discusses this potential with a theranostics expert.

Theranostics 101: Combining Therapeutics and Diagnostics to Treat Prostate Cancer

November 25th 2020, 7:00pm


Theranostics, or the method of using one radioactive drug to diagnose a malignancy and a second radioactive drug to treat that cancer, is gaining in popularity in the treatment of prostate cancer.